Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1580 Views
eMediNexus 13 December 2017
The US Food and Drug Administration (FDA) has expanded the indication of the HIV drug raltegravir (Isentress, Merck) beyond adults and children aged 2 to 18 years to newborns weighing at least 2 kg making it the only approved integrase inhibitor for HIV-1 treatment in this population group, to be used in combination with other antiretroviral agents.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}